Zura Bio Limited (NASDAQ:ZURA) Director Purchases $499,998.72 in Stock

Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi bought 159,744 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was acquired at an average cost of $3.13 per share, for a total transaction of $499,998.72. Following the completion of the transaction, the director now owns 777,384 shares in the company, valued at $2,433,211.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Zura Bio Price Performance

Zura Bio stock traded down $0.17 during midday trading on Wednesday, hitting $3.31. The company’s stock had a trading volume of 826,726 shares, compared to its average volume of 278,140. The stock’s 50-day moving average price is $3.21 and its 200-day moving average price is $4.04. Zura Bio Limited has a 12 month low of $2.00 and a 12 month high of $14.00.

Analysts Set New Price Targets

Separately, Oppenheimer reissued an “outperform” rating and set a $16.00 price target (down from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $16.40.

Institutional Trading of Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Forefront Analytics LLC grew its stake in shares of Zura Bio by 46.8% in the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after buying an additional 6,765 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Zura Bio by 15.4% in the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock valued at $8,518,000 after buying an additional 244,000 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in shares of Zura Bio in the 3rd quarter valued at approximately $65,000. Eisler Capital US LLC bought a new stake in shares of Zura Bio in the 3rd quarter valued at approximately $660,000. Finally, Silverarc Capital Management LLC boosted its position in Zura Bio by 152.5% during the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after purchasing an additional 244,040 shares during the period. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.